Quarterly ResultAug 6, 2026, 07:26 AM
Precision BioSciences Q2 Net Loss $(32.65)M; Extends Loan Maturity to 2029
AI Summary
Precision BioSciences reported a net loss of $(32.65) million for Q2 2026, widening from $(23.52) million in Q2 2025. The company extended the maturity date of its $22.5 million term loan to December 31, 2029, enhancing financial flexibility. Cash and cash equivalents decreased to $86.08 million, while total liabilities increased significantly due to a rise in warrant liability. The company recognized $6.8 million in revenue from a TG Therapeutics clinical milestone and $4.0 million from an agriculture collaboration.
Key Highlights
- Net loss for Q2 2026 was $(32.65) million, up from $(23.52) million in Q2 2025.
- Extended $22.5 million term loan maturity from June 2027 to December 2029.
- Cash and cash equivalents stood at $86.08 million as of June 30, 2026.
- Warrant liability increased to $36.69 million from $15.70 million since Dec 31, 2025.
- H1 2026 revenue was $10.84 million, significantly up from $0.05 million in H1 2025.
- Received $7.5 million from TG Therapeutics for a clinical milestone.
- Recognized $4.0 million revenue from a concluded agriculture collaboration.
Price Impact
More from DTIL